Abstract

Background Nearly 12% of Americans suffer from peripheral arterial disease (PAD) and many are not eligible for conventional angioplasty or surgical bypass. Microencapsulated stem cell (SC) therapy offers a novel means to transplant allogeneic SCs to avoid immunorejection and enable image tracking. However, quantitative evaluation of capsule fate is elusive. Here we explore c-arm CT and 19F-MRI for serial evaluation of dual X-ray/MR-visible SC microcapsules (XMRCaps) in a rabbit PAD model.

Highlights

  • Nearly 12% of Americans suffer from peripheral arterial disease (PAD) and many are not eligible for conventional angioplasty or surgical bypass

  • In vitro validation studies were performed in a phantom consisting of known quantities of X-ray/MR-visible SC microcapsules (XMRCaps)

  • C-arm CT images were acquired and reconstructed at 0.46 mm3 voxel size. 19F MRI was acquired with a flexible, 4-channel Tx/Rx 19F coil (3D TrueFISP, Siemens Tim Trio, 4.1 ms TR; 2.0 ms TE; 32 averages) in the coronal plane. 1H MRI was acquired with the system body or body matrix coil

Read more

Summary

Background

12% of Americans suffer from peripheral arterial disease (PAD) and many are not eligible for conventional angioplasty or surgical bypass. Microencapsulated stem cell (SC) therapy offers a novel means to transplant allogeneic SCs to avoid immunorejection and enable image tracking. Quantitative evaluation of capsule fate is elusive. We explore c-arm CT and 19F-MRI for serial evaluation of dual X-ray/MR-visible SC microcapsules (XMRCaps) in a rabbit PAD model

Methods
Results
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.